- Home
- ONCO vs APVO Comparison
ONCO vs APVO Comparison
Compare ONCO & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- APVO
- Stock Information
- Founded
- ONCO 2018
- APVO 2016
- Country
- ONCO United States
- APVO United States
- Employees
- ONCO N/A
- APVO N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- ONCO Health Care
- APVO Health Care
- Exchange
- ONCO Nasdaq
- APVO Nasdaq
- Market Cap
- ONCO 3.6M
- APVO 5.4M
- IPO Year
- ONCO 2022
- APVO N/A
- Fundamental
- Price
- ONCO $0.13
- APVO $2.38
- Analyst Decision
- ONCO
- APVO Strong Buy
- Analyst Count
- ONCO 0
- APVO 1
- Target Price
- ONCO N/A
- APVO $296.00
- AVG Volume (30 Days)
- ONCO 2.1M
- APVO 47.1K
- Earning Date
- ONCO 04-10-2025
- APVO 05-07-2025
- Dividend Yield
- ONCO N/A
- APVO N/A
- EPS Growth
- ONCO N/A
- APVO N/A
- EPS
- ONCO N/A
- APVO N/A
- Revenue
- ONCO $1,870,605.00
- APVO N/A
- Revenue This Year
- ONCO N/A
- APVO N/A
- Revenue Next Year
- ONCO N/A
- APVO N/A
- P/E Ratio
- ONCO N/A
- APVO N/A
- Revenue Growth
- ONCO N/A
- APVO N/A
- 52 Week Low
- ONCO $0.13
- APVO $2.35
- 52 Week High
- ONCO $21.40
- APVO $207.35
- Technical
- Relative Strength Index (RSI)
- ONCO 18.44
- APVO 28.55
- Support Level
- ONCO $0.16
- APVO $3.02
- Resistance Level
- ONCO $0.25
- APVO $4.00
- Average True Range (ATR)
- ONCO 0.03
- APVO 0.27
- MACD
- ONCO -0.01
- APVO -0.03
- Stochastic Oscillator
- ONCO 1.56
- APVO 1.58
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.